Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
6.72
+0.05 (0.75%)
Aug 14, 2026, 4:00 PM EDT - Market closed
Eupraxia Pharmaceuticals Employees
Eupraxia Pharmaceuticals had 49 employees as of December 31, 2025. The number of employees increased by 16 or 48.48% compared to the previous year.
Employees
49
Change (1Y)
16
Growth (1Y)
48.48%
Revenue / Employee
n/a
Profits / Employee
-$1,050,610
Market Cap
442.16M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 49 | 16 | 48.48% | 49 | 0 |
| Dec 31, 2024 | 33 | 4 | 13.79% | 33 | 0 |
| Dec 31, 2023 | 29 | 8 | 38.10% | 29 | 0 |
| Dec 31, 2022 | 21 | 0 | - | 21 | 0 |
| Dec 31, 2021 | 21 | 9 | 75.00% | 19 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| Puma Biotechnology | 179 |
| Ocugen | 116 |
| Editas Medicine | 87 |
| Larimar Therapeutics | 71 |
| Prothena Corporation | 67 |
| X4 Pharmaceuticals | 45 |
| Inhibikase Therapeutics | 35 |
EPRX News
- 3 days ago - Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients - GlobeNewsWire
- 4 days ago - Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 4 days ago - Eupraxia Pharmaceuticals Earnings release: Q2 2026 - Filings
- 4 days ago - Eupraxia Pharmaceuticals Registration statement: Q2 2026 - Filings
- 4 days ago - Eupraxia Pharmaceuticals Registration statement: Q2 2026 - Filings
- 10 days ago - Eupraxia Pharmaceuticals Registration statement: Registration filing - Filings
- 10 days ago - Eupraxia Pharmaceuticals files $300M mixed securities shelf - TheFly
- 17 days ago - Eupraxia Pharmaceuticals Slides: Investor presentation - Filings